2019, Number 1
PDF size: 125.74 Kb.
ABSTRACTThe residual risk of transfusion-related infections has decreased dramatically in countries that have routinely implemented serological screening. Most of the donation in Mexico is from replacement practice, a risk factor for positive serology. In Mexico, the altruistic donation is only 2.7%. The heterogeneity of technical factors, regional factors and internal policies of each center influences the variability of data on the prevalence of positive screening, as well as the prevalence of confirmed cases. The main advantage of nucleic acid technology is the detection of donors in the period of serological window or occult infections, being occult hepatitis reports in Mexican donors from 1 to 3.4%. The limitation of available technology, the scope of the clinic and perspectives, invites us to improve technology and health policies in the interest of transfusion safety.
Sosa-Jurado F, Rosas-Murrieta NH, Guzman-Flores B, Perez-Zempoaltecalt C, Sanchez-Torres AP, Ramirez Rosete L, et al. Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA. Hepat Mon. 2016;16(6):e-36942. DOI: 10.5812/hepatmon.36942
Hernández-Becerril N, Mejía AM, Ballinas-Verdugo MA, Garza-Murillo V, Manilla-Toquero E, López R, et al. Blood transfusion and iatrogenic risks in Mexico city. Anti- Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz. 2005; 100(2):111-6.
Alvarado-Esquivel C, Rascón-Careaga A, Hernández- Tinoco J, Corella-Madueño MAG, Sánchez-Anguiano LF, Aldana-Madrid ML, et al. Seroprevalence and Associated Risk Factors for Toxoplasma gondii Infection in Healthy Blood Donors: A Cross-Sectional Study in Sonora, Mexico. Biomed Res Int. 2016;2016:9597276. DOI: 10.1155/2016/9597276
Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50 (7):1495-504. DOI: 10.1111/j.1537-2995.2010.02622.x